Skip to main content
. Author manuscript; available in PMC: 2020 Jan 8.
Published in final edited form as: Biochem Biophys Res Commun. 2018 Dec 3;508(2):614–619. doi: 10.1016/j.bbrc.2018.11.125

Figure 1. The platelet NLRP3 inflammasome is upregulated following FAL via TLR4.

Figure 1.

(A) Platelet caspase-1 activity (measured by FLICA assay) is upregulated in mice subjected to FAL. Platelet caspase-1 activity is suppressed in the presence of the NLRP3 inhibitor MCC950 and the caspase-1 inhibitor YVAD. (B) Expression of cleaved IL-1β in platelets is increased in mice subjected to FAL and decreased in the presence of the NLRP3 inhibitor MCC950. (C) Platelet caspase-1 activity in the presence or absence of FAL is downregulated in TLR4 PF4 mice as compared to TLR4 Flox controls. (D) Downregulated platelet caspase-1 activity in TLR4 PF4 mice is restored by the NLRP3 activator Nigericin,which does not occur in platelets derived from TLR4 Flox controls. Data are presented as mean ±SD for N≥3 and at least three separate experiments in all studies. *p< 0.05, **p < 0.01,***p < 0.001 (2-way ANOVA with Bonferroni post-hoc test in A, C, D).